Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antipsychotic medication |
| gptkbp:approvalYear |
2009
|
| gptkbp:approvedBy |
gptkb:United_States
|
| gptkbp:ATCCode |
N05AE04
|
| gptkbp:brand |
Fanapt
|
| gptkbp:CASNumber |
133454-47-4
|
| gptkbp:category |
second-generation antipsychotic
|
| gptkbp:contraindication |
QT prolongation
known hypersensitivity to iloperidone |
| gptkbp:developer |
gptkb:Vanda_Pharmaceuticals
gptkb:Novartis |
| gptkbp:drugClass |
antipsychotic medication
|
| gptkbp:eliminationHalfLife |
18 hours
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:hasMolecularFormula |
C24H27FN2O4
|
| https://www.w3.org/2000/01/rdf-schema#label |
iloperidone
|
| gptkbp:interactsWith |
CYP2D6 inhibitors
CYP3A4 inhibitors other QT-prolonging drugs |
| gptkbp:IUPACName |
1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone
|
| gptkbp:KEGGID |
D08913
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist |
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
95%
|
| gptkbp:PubChem_CID |
CHEMBL1201192
141319 160855 DB04946 |
| gptkbp:riskFactor |
neuroleptic malignant syndrome
tardive dyskinesia leukopenia hyperglycemia QT interval prolongation |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:orthostatic_hypotension
dizziness weight gain tachycardia somnolence |
| gptkbp:synonym |
Fanapt
HP 873 Zomaril |
| gptkbp:UNII |
71IH826FEG
|
| gptkbp:usedFor |
treatment of schizophrenia
|
| gptkbp:bfsParent |
gptkb:N05AX
gptkb:5-HT2C_receptor |
| gptkbp:bfsLayer |
7
|